Bisphosphonates, cancer, and osteonecrosis--a single practice experience.
Intravenous bisphosphonates have come into increasing use to protect cancer patients from adverse boney events. The prevalence of use, demographics of a treatment population, and occurrence of a particular side effect are explored in this article.
Guarino
Michael J
MJ
Medical Oncology Hematology Consultants, Newark, DE, USA.
Hill
Constance E
CE
Patel
Ketan
K
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001706:Biopsy; D003646:Debridement; D004164:Diphosphonates / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007093:Imidazoles / Q000009:adverse effects* / Q000627:therapeutic use; D007262:Infusions, Intravenous; D008297:Male; D008336:Mandibular Diseases / Q000139:chemically induced* / Q000473:pathology / Q000601:surgery; D008439:Maxillary Diseases / Q000139:chemically induced* / Q000473:pathology / Q000601:surgery; D008875:Middle Aged; D009369:Neoplasms / Q000188:drug therapy*; D010020:Osteonecrosis / Q000139:chemically induced* / Q000473:pathology / Q000601:surgery; D000077268:Pamidronate; D000077211:Zoledronic Acid
D000970:Antineoplastic Agents; D004164:Diphosphonates; D007093:Imidazoles; D000077211:Zoledronic Acid; D000077268:Pamidronate